Integrating 2D human stem cell model to enlarge R&D platform tools

ExAdEx-Innov announces the signature of a licence agreement with CNRS Innovation on human stem cell model to enlarge R&D platform tools from cells to tissue

With the aim of integrating complementary models to its proprietary platform and strengthening the panel of research and development projects covered, ExAdEx-Innov has signed a licence agreement with CNRS Innovation for a patented application of 2D stem cell model hMADS.

Human Multipotent Adipose-Derived Stem (hMADS) were isolated from donor adipose tissue and extensively studied by the academic research laboratory managed by ExAdEx-Innov co-founder and Scientific Advisor Christian Dani, PhD, and Director of Research at INSERM, co-inventor of the patents covering their application. 

hMADS cells are a powerful 2D tool for screening of compounds in a standardized, time-effective and cost-effective manner, that perfectly complements ExAdEx 3D real human fat tissue organoids, for a comprehensive investigation on adipose tissue from screening up to mechanistic studies.

White adipocytes derived from hMADS can switch to a brown adipocyte phenotype that is associated with an increased energy expenditure. hMADS can thus be used to screen for drugs and active ingredients stimulating energy expenditure capacity, which could help to dissipate excess caloric intake in several clinical applications (nutrition, pharmaceutical approaches, cosmetics).

« The signature of a licence agreement with CNRS Innovation on hMADS cells is an important step in the development of our R&D platform, as it will allow us to provide a full panel of complementary tools and know-how to our clients and collaborators, in particular in a field such as energy expenditure that has become a hot topic in research to address major societal challenges such as weight management, overweight and obesity », states Vincent Dani, CEO and co-founder of ExAdEx-Innov.